Status:
UNKNOWN
Lowering InterLeukin-1 Receptor Antagonist Concentrations After TB Treatment Onset
Lead Sponsor:
ANRS, Emerging Infectious Diseases
Collaborating Sponsors:
Institut Pasteur, Cambodia
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Tuberculosis
Eligibility:
All Genders
18-99 years
Brief Summary
Despite marked improvements in the diagnosis of tuberculosis there are difficulties in diagnosing and monitoring treatment outcome among TB patients. The use of immunological biomarkers alone or in co...
Detailed Description
The HIV/AIDS epidemic and Tuberculosis (TB) remain important challenges for global public health and are strongly linked. Despite marked improvements in the diagnosis of tuberculosis, there are diffic...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Evidence of TB, with: positive Xpert MTB/RIF
- For HIV infected patients:
- ART-naïve
- Regardless of CD4 cell counts
- Written informed consent
- Willingness to be followed up in the study clinics for 6 months after inclusion
Exclusion
- Mycobacterium tuberculosis strain resistant to rifampin with Xpert MTB/RIF
- Ongoing TB treatment
- Overt evidence of other ongoing opportunistic infections
- Pregnant or breastfeeding women
- Karnofsky score ≤ 30
- Person unable to understand the study
- Person currently participating in clinical trial
- Females on oestroprogestative and progestative hormonal contraception
Key Trial Info
Start Date :
January 21 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04015713
Start Date
January 21 2020
End Date
March 1 2021
Last Update
February 6 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Pasteur Cambodge
Phnom Penh, Cambodia
2
CEPREF/Programme PACCI
Abidjan, Côte d’Ivoire